Dose escalation trial of cyclophosphamide with sagramostim in the treatment of central nervous system (CNS) neoplasms

Daniel H Lachance, D. Oette, S. C. Schold, M. Brown, J. Kurtzberg, M. L. Graham, R. Tien, G. Felsberg, O. M. Colvin, A. Moghrabi, I. Browning, B. Hockenberger, E. Stewart, L. Ferrell, T. Kerby, M. Duncan-Brown, B. Golembe, H. Fuchs, H. S. Friedman

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We conducted a dose escalation trial of cyclophosphamide plus Sargramostim in the therapy of patients with newly diagnosed or recurrent central nervous system tumors. Cyclophosphamide was administered at doses ranging between 1.0 and 2.5 g/m2 daily for two doses. Sargramostim was administered at a fixed dose of 250 μg/m2 subcutaneously twice a day beginning 24 hours after the second cyclophosphamide dose and continuing through the leukocyte nadir until the absolute neutrophil count (ANC) was >1,000 cells/μl for two consecutive days. The MTD for patients who had not received any prior chemotherapy and who had received either no radiotherapy or radiotherapy confined to the cranium was 2.0 g/m2 daily for two doses. The MTD for patients previously treated with chemotherapy or neuraxis radiotherapy was also 2.0 g/m2 daily for two doses. Responses were seen in patients with medulloblastoma (8/9), glioblastoma multiforme (2/13), germinoma (1/1), and pineoblastoma (1/2).

Original languageEnglish (US)
Pages (from-to)241-247
Number of pages7
JournalMedical and Pediatric Oncology
Volume24
Issue number4
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Central Nervous System Neoplasms
Cyclophosphamide
Radiotherapy
Germinoma
Pinealoma
Drug Therapy
Medulloblastoma
Therapeutics
Glioblastoma
Skull
Neutrophils
Leukocytes
sargramostim

Keywords

  • CNS tumor
  • cyclophosphamide
  • Sagramostim

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research

Cite this

Dose escalation trial of cyclophosphamide with sagramostim in the treatment of central nervous system (CNS) neoplasms. / Lachance, Daniel H; Oette, D.; Schold, S. C.; Brown, M.; Kurtzberg, J.; Graham, M. L.; Tien, R.; Felsberg, G.; Colvin, O. M.; Moghrabi, A.; Browning, I.; Hockenberger, B.; Stewart, E.; Ferrell, L.; Kerby, T.; Duncan-Brown, M.; Golembe, B.; Fuchs, H.; Friedman, H. S.

In: Medical and Pediatric Oncology, Vol. 24, No. 4, 1995, p. 241-247.

Research output: Contribution to journalArticle

Lachance, DH, Oette, D, Schold, SC, Brown, M, Kurtzberg, J, Graham, ML, Tien, R, Felsberg, G, Colvin, OM, Moghrabi, A, Browning, I, Hockenberger, B, Stewart, E, Ferrell, L, Kerby, T, Duncan-Brown, M, Golembe, B, Fuchs, H & Friedman, HS 1995, 'Dose escalation trial of cyclophosphamide with sagramostim in the treatment of central nervous system (CNS) neoplasms', Medical and Pediatric Oncology, vol. 24, no. 4, pp. 241-247. https://doi.org/10.1002/mpo.2950240406
Lachance, Daniel H ; Oette, D. ; Schold, S. C. ; Brown, M. ; Kurtzberg, J. ; Graham, M. L. ; Tien, R. ; Felsberg, G. ; Colvin, O. M. ; Moghrabi, A. ; Browning, I. ; Hockenberger, B. ; Stewart, E. ; Ferrell, L. ; Kerby, T. ; Duncan-Brown, M. ; Golembe, B. ; Fuchs, H. ; Friedman, H. S. / Dose escalation trial of cyclophosphamide with sagramostim in the treatment of central nervous system (CNS) neoplasms. In: Medical and Pediatric Oncology. 1995 ; Vol. 24, No. 4. pp. 241-247.
@article{bc52b0795eb14387a772fe936a05513b,
title = "Dose escalation trial of cyclophosphamide with sagramostim in the treatment of central nervous system (CNS) neoplasms",
abstract = "We conducted a dose escalation trial of cyclophosphamide plus Sargramostim in the therapy of patients with newly diagnosed or recurrent central nervous system tumors. Cyclophosphamide was administered at doses ranging between 1.0 and 2.5 g/m2 daily for two doses. Sargramostim was administered at a fixed dose of 250 μg/m2 subcutaneously twice a day beginning 24 hours after the second cyclophosphamide dose and continuing through the leukocyte nadir until the absolute neutrophil count (ANC) was >1,000 cells/μl for two consecutive days. The MTD for patients who had not received any prior chemotherapy and who had received either no radiotherapy or radiotherapy confined to the cranium was 2.0 g/m2 daily for two doses. The MTD for patients previously treated with chemotherapy or neuraxis radiotherapy was also 2.0 g/m2 daily for two doses. Responses were seen in patients with medulloblastoma (8/9), glioblastoma multiforme (2/13), germinoma (1/1), and pineoblastoma (1/2).",
keywords = "CNS tumor, cyclophosphamide, Sagramostim",
author = "Lachance, {Daniel H} and D. Oette and Schold, {S. C.} and M. Brown and J. Kurtzberg and Graham, {M. L.} and R. Tien and G. Felsberg and Colvin, {O. M.} and A. Moghrabi and I. Browning and B. Hockenberger and E. Stewart and L. Ferrell and T. Kerby and M. Duncan-Brown and B. Golembe and H. Fuchs and Friedman, {H. S.}",
year = "1995",
doi = "10.1002/mpo.2950240406",
language = "English (US)",
volume = "24",
pages = "241--247",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - Dose escalation trial of cyclophosphamide with sagramostim in the treatment of central nervous system (CNS) neoplasms

AU - Lachance, Daniel H

AU - Oette, D.

AU - Schold, S. C.

AU - Brown, M.

AU - Kurtzberg, J.

AU - Graham, M. L.

AU - Tien, R.

AU - Felsberg, G.

AU - Colvin, O. M.

AU - Moghrabi, A.

AU - Browning, I.

AU - Hockenberger, B.

AU - Stewart, E.

AU - Ferrell, L.

AU - Kerby, T.

AU - Duncan-Brown, M.

AU - Golembe, B.

AU - Fuchs, H.

AU - Friedman, H. S.

PY - 1995

Y1 - 1995

N2 - We conducted a dose escalation trial of cyclophosphamide plus Sargramostim in the therapy of patients with newly diagnosed or recurrent central nervous system tumors. Cyclophosphamide was administered at doses ranging between 1.0 and 2.5 g/m2 daily for two doses. Sargramostim was administered at a fixed dose of 250 μg/m2 subcutaneously twice a day beginning 24 hours after the second cyclophosphamide dose and continuing through the leukocyte nadir until the absolute neutrophil count (ANC) was >1,000 cells/μl for two consecutive days. The MTD for patients who had not received any prior chemotherapy and who had received either no radiotherapy or radiotherapy confined to the cranium was 2.0 g/m2 daily for two doses. The MTD for patients previously treated with chemotherapy or neuraxis radiotherapy was also 2.0 g/m2 daily for two doses. Responses were seen in patients with medulloblastoma (8/9), glioblastoma multiforme (2/13), germinoma (1/1), and pineoblastoma (1/2).

AB - We conducted a dose escalation trial of cyclophosphamide plus Sargramostim in the therapy of patients with newly diagnosed or recurrent central nervous system tumors. Cyclophosphamide was administered at doses ranging between 1.0 and 2.5 g/m2 daily for two doses. Sargramostim was administered at a fixed dose of 250 μg/m2 subcutaneously twice a day beginning 24 hours after the second cyclophosphamide dose and continuing through the leukocyte nadir until the absolute neutrophil count (ANC) was >1,000 cells/μl for two consecutive days. The MTD for patients who had not received any prior chemotherapy and who had received either no radiotherapy or radiotherapy confined to the cranium was 2.0 g/m2 daily for two doses. The MTD for patients previously treated with chemotherapy or neuraxis radiotherapy was also 2.0 g/m2 daily for two doses. Responses were seen in patients with medulloblastoma (8/9), glioblastoma multiforme (2/13), germinoma (1/1), and pineoblastoma (1/2).

KW - CNS tumor

KW - cyclophosphamide

KW - Sagramostim

UR - http://www.scopus.com/inward/record.url?scp=0028960661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028960661&partnerID=8YFLogxK

U2 - 10.1002/mpo.2950240406

DO - 10.1002/mpo.2950240406

M3 - Article

C2 - 7700169

AN - SCOPUS:0028960661

VL - 24

SP - 241

EP - 247

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 4

ER -